Skip to content
Search

Latest Stories

Ganguly shouldn't have spoken on Kohli captaincy issue: Vengsarkar

Ganguly shouldn't have spoken on Kohli captaincy issue: Vengsarkar

Former India captain and chairman of selectors Dilip Vengsarkar feels that BCCI president Sourav Ganguly wasn't right in airing his views on behalf of national selectors Virat Kohli's captaincy saga which has triggered a controversy.

Ahead of their departure to South Africa, Virat Kohli in a media conference said that no one from BCCI told him not to quit T20 captaincy, contrary to Ganguly's claims that he had spoken to the skipper on the issue.


Vengsarkar said that Ganguly had no business to speak in the matter.

"The thing is that Ganguly had no business to speak on behalf of the selection committee. He is the BCCI president. Any issue about selection or captaincy, it's the chairman of selection committee Chetan Sharma, who should speak," Vengsarkar, a veteran of 116 Tests said on Wednesday.

Earlier, Ganguly, himself a former India captain had said that Kohli's decision to not reconsider giving up T20 captaincy prompted the selectors to go for Rohit as the sole white-ball skipper as two different captains in the two formats would have led to "too much leadership."

"We had requested Virat not to step down as T20 captain but he didn't want to continue as captain. So, the selectors felt that they cannot have two white ball captains in two white-ball formats. That's too much of leadership," the BCCI president had told PTI.

Vengsarkar believes that the prerogative of selecting or dropping any player rests solely with selection committee.

"A captain is selected or removed by the selection committee and that is not Ganguly's jurisdiction at all," said the former Mumbai legendary right-handed batter.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less